Appetite Regulation and Mycoprotein

Appetite Clinical Trial

— mycoprotein  

Official title:

Appetite Regulation and Mycoprotein

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02053025
• Other study ID #: CRO1332
• Status: Completed
• Phase: N/A
• Start date: March 2010
• Est. completion date: October 2012

Study information

• Verified date: October 2019
• Source: Imperial College London
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the effect of eating various levels of mycoprotein (Quorn) on feelings of appetite, energy intake and levels of gut hormones in overweight volunteers.

Description:

Owing to its relatively high protein and fibre content, mycoprotein presents an attractive food product to improve appetite regulation and postprandial glycaemic and insulin responses in overweight and obese individuals at risk of developing T2DM

Recruitment information / eligibility

• Status: Completed
• Enrollment: 52
• Est. completion date: October 2012
• Est. primary completion date: October 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Males and females between the ages of 18 and 65

• body mass index (BMI) 25-32kg/m2

• Weight stable over the past 6 months

• No known major illness or eating disorder nor on any medication that may impact on appetite or hormone levels.

• No paracetamol or other analgesic in the previous 48 hours

• A score of <2.5 in the Dutch Eating Behaviour Questionnaire (DEBQ)

• A score of <2 in the SCOFF questionnaire

Exclusion Criteria:

• Persons outside the age and BMI ranges stated above

• Pregnant and lactating women

• Weight variation of greater than 5% in the last 6 months

• Any diagnosed major illness

• Any paracetamol or analgesic intake in the last 48 hours

• Diagnosed eating disorder

• Allergy to mycoprotein or mushrooms

• Regular consumption of Quorn products

• Dislike of any of the test foods or drinks

• A score of >2.5 in the Dutch Eating Behaviour questionnaire

• A score of 2 or more in the SCOFF questionaire

Related Conditions & MeSH terms

• Appetite
• Energy Intake

Intervention

Dietary Supplement:
• mycoprotein

• control protein

Locations

Country	Name	City	State
United Kingdom	Imperial College NIHR CRF	London

Sponsors (1)

Lead Sponsor	Collaborator
Imperial College London

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Bottin JH, Swann JR, Cropp E, Chambers ES, Ford HE, Ghatei MA, Frost GS. Mycoprotein reduces energy intake and postprandial insulin release without altering glucagon-like peptide-1 and peptide tyrosine-tyrosine concentrations in healthy overweight and obe — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Energy intake at ad-libitum meal	Energy intake will be assessed during an ad-libitum meal at 180 minutes at the end of each study visit. Participants will be offered a meal in excess and asked to eat until they feel comfortably full. The meal will be weighed before and after consumption and energy intake will be calculated from the manufacturer's reported nutritional composition.	upon completion of all participants, expected timeframe: 2 years
Secondary	Glucagon-like peptide-1 (GLP-1)	Plasma glucagon-like peptide-1 (GLP-1) concentrations will be measured by radioimmunoassay (RIA) at the end of the study	upon completion of all participants, expected at 2 years
Secondary	peptide tyrosine-tyrosine (PYY) levels	Plasma peptide tyrosine-tyrosine (PYY) concentrations will be measured by radioimmunoassay (RIA) at the end of the study	upon completion of all participants, expected at 2 years